We are live on ! Find out more
SLDB icon

Solid Biosciences

71 hedge funds and large institutions have $46.9M invested in Solid Biosciences in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more call options, than puts

Call options by funds: $1.62M | Put options by funds: $782K

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

3% more funds holding

Funds holding: 6971 (+2)

0% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 22

0.04% less ownership

Funds ownership: 2.88%2.84% (-0.04%)

47% less capital invested

Capital invested by funds: $88.5M → $46.9M (-$41.5M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
71
Holders Change
+2
Holders Change %
+2.9%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
14
Increased
22
Reduced
22
Closed
11
Calls
$1.62M
Puts
$782K
Net Calls
+$834K
Net Calls Change
+$188K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$10.9M
BCLSI
2
Bain Capital Life Sciences Investors
Massachusetts
$9.25M
BlackRock
3
BlackRock
New York
$4.58M -$10.3K -208 -0.2%
AG
4
Artal Group
Luxembourg
$4.3M
BC
5
Boxer Capital
California
$3.66M +$1.65M +33,334 +48%
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.07M +$8.31K +168 +0.3%
Morgan Stanley
7
Morgan Stanley
New York
$1.34M -$442K -8,938 -19%
IC
8
Ikarian Capital
Texas
$1.29M +$1.78M +35,937 New
State Street
9
State Street
Massachusetts
$854K +$29.6K +598 +3%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$741K -$367K -7,425 -26%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$732K +$138K +2,787 +16%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$706K +$67.6K +1,365 +7%
JP Morgan Chase
13
JP Morgan Chase
New York
$646K +$537K +10,845 +151%
Millennium Management
14
Millennium Management
New York
$569K -$2.95M -59,542 -79%
Northern Trust
15
Northern Trust
Illinois
$566K +$17K +344 +2%
Deutsche Bank
16
Deutsche Bank
Germany
$312K -$152K -3,072 -26%
Wells Fargo
17
Wells Fargo
California
$299K +$168K +3,397 +69%
PP
18
PDT Partners
New York
$244K -$58.4K -1,180 -15%
Charles Schwab
19
Charles Schwab
California
$214K +$4.16K +84 +1%
Renaissance Technologies
20
Renaissance Technologies
New York
$207K +$94.1K +1,901 +49%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$206K +$242K +4,894 +574%
Two Sigma Investments
22
Two Sigma Investments
New York
$202K +$42.9K +867 +18%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$199K +$34.7K +701 +14%
Citadel Advisors
24
Citadel Advisors
Florida
$192K -$393K -7,947 -60%
SIM
25
Spark Investment Management
New York
$188K -$197K -3,988 -43%

SLDB Hedge Fund Activity: Q1 2020 in Review

71 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2020, worth a combined $46.9M — down 47% from $88.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new SLDB positions and 11 closed out — a net gain of 3 holders — while 22 added to existing stakes and 22 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.78M. The largest seller was Millennium Management, cutting an estimated $2.95M.

  • 71 institutional investors held Solid Biosciences (SLDB) as of Q1 2020, up from 69 in Q4 2019.
  • Funds reported $46.9M of Solid Biosciences stock for Q1 2020, down 47% quarter-over-quarter.
  • 14 funds opened new Solid Biosciences positions in Q1 2020 and 11 closed out, a net change of +3 holders.
  • The largest Solid Biosciences buyer in Q1 2020 was Ikarian Capital, an estimated $1.78M added.
  • The largest Solid Biosciences seller in Q1 2020 was Millennium Management, an estimated $2.95M sold.

Based on aggregated 13F filings for Q1 2020.